← Issue №9/ week of Aug 30, 2026/Endoscopy

Mucin phenotype stratifies histological malignancy in superficial non-ampullary duodenal epithelial tumors: a prospective study.

From GI Signals issue №9: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy prospective cohort · n=401 · Aug 27, 2026 · J Gastroenterology · IF 5.7

Mucin phenotype stratifies histological malignancy in superficial non-ampullary duodenal epithelial tumors: a prospective study.

New evidencebiomarker
Clinical takeawayConsider mucin phenotype (G-type vs I-type) in pretreatment risk stratification for SNADETs, especially when closed-loop structure, absence of white opaque substance on IEE-ME, or protruding morphology are present.
What it foundG-type SNADETs (15.5% of lesions) had a markedly higher frequency of histological malignancy beyond Vienna category 4.1 (high-grade dysplasia, carcinoma in situ, submucosal invasive carcinoma) compared to I-type (P < 0.0001), with risk increasing stepwise with gastric phenotypic components.
ContextRefines risk stratification for SNADETs, which lacked clear biological malignancy markers; supports phenotype-oriented endoscopic diagnosis.
Emergingsuggested applicable standard· ESGE/ESGENA 2026 (PMID 42480549); ESGE/ESGENA/ESA NAAP 2015; ASGE 2018; ASA 2018 moderate sedation; multisociety GLP-1 perioperative guidance 2024

Decision at stakerisk stratification and treatment planning for superficial non-ampullary duodenal epithelial tumors

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Scale pre-sedation assessment, regimen and monitoring to patient risk and procedure complexity. Assess ASA class, Mallampati, BMI, OSA risk and fasting status before every sedated procedure. Propofol AND midazolam-with-opiate are both strongly recommended; propofol as first line is conditioned on national legislation and staffing, not on demonstrated superiority. Consider remimazolam in the elderly and in cardiorespiratory comorbidity. Whoever administers sedation must be able to rescue a patient one level deeper than intended. Involve an anesthesiology specialist for emergency endoscopy with increased aspiration risk, hemodynamic instability, OR significant comorbidities, and electively for ASA >=3, Mallampati >=3, severe OSA or anticipated difficult airway. Individualize GLP-1 receptor agonist management rather than withholding blindly. Discharge against a scoring system with an accompanying adult and 24-hour restrictions.

ESGE/ESGENA 2026 (PMID 42480549); ESGE/ESGENA/ESA NAAP 2015; ASGE 2018; ASA 2018 moderate sedation; multisociety GLP-1 perioperative guidance 2024 ↗
Nakayama A … Kato M · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
← Read the whole of issue №9 Every paper GI Signals surfaces gets a page like this one. All issues